Key Takeaways From FDA's Latest Social Media Warnings
On Oct. 31, the U.S. Food and Drug Administration's Office of Prescription Drug Promotion posted an untitled letter taking issue with Merz Pharmaceuticals GmbH's social media promotion of Xeomin, an injection...To view the full article, register now.
Already a subscriber? Click here to view full article